Discover investment opportunities in Best Psychedelic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Psychedelic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Psychedelic Stocks using our Smart AI Filter.
6 stocks found for "Best Psychedelic Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.02 | ±100.0% | -0.3 | 0.00% | |||
0.49 | ±66.7% | -1.1 | 0.00% | |||
1.28 | ±88.5% | -5.2 | 0.00% | |||
1.18 | ±85.7% | -17.1 | 0.00% | |||
1.17 | ±100.0% | -4.1 | 0.00% | |||
0.82 | ±100.0% | -13.0 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What are the key drivers for COMPASS Pathways (CMPS) stock performance?
A: COMPASS Pathways focuses on psychedelic therapies, with its most advanced program targeting treatment-resistant depression. Key drivers include clinical trial outcomes, regulatory progress, and partnerships. Investors watch for updates on psilocybin therapy and its potential market approval.
Q: How does Cybin (CYBN) differentiate itself in the psychedelic drug market?
A: Cybin differentiates itself by focusing on novel psychedelic compounds and delivery systems. Their ongoing research into faster-acting mental health treatments positions the company uniquely. Key valuation points include its R&D development pipeline and collaborations with academic institutions.
Q: What potential growth opportunities exist for MindMed (MNMD)?
A: MindMed is engaged in developing psychedelic-inspired medicines and digital therapeutics. Its diverse pipeline targeting mental health issues and addiction, along with strategic partnerships, provides potential growth. Progress in clinical trials could impact its market performance significantly.
Q: Why might atai Life Sciences (ATAI) attract investor interest?
A: atai Life Sciences is a biotech platform company leveraging psychedelics for mental health treatments. Investors are interested in its robust pipeline, diverse subsidiaries, and strategic partnerships. Regulatory approvals and clinical trials are pivotal for investor confidence and stock movement.
Q: Does Relmada Therapeutics (RLMD) offer any unique value proposition in the sector?
A: Relmada Therapeutics focuses on developing novel treatments for depression and other central nervous system disorders, including its lead product, REL-1017. This late-stage asset, combined with collaborations, provides a unique value proposition, especially if clinical results are favorable.
Q: What distinguishes GH Research (GHRS) in the psychedelic therapy landscape?
A: GH Research focuses on 5-MeO-DMT therapy for treatment-resistant depression. Its streamlined pipeline and potential for rapid onset of therapeutic effects distinguish it from peers. Success in clinical trials could be a significant value driver for its stock.
atai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read moreThe consensus price target hints at an 831.4% upside potential for Cybin Inc. (CYBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read moreThe average of price targets set by Wall Street analysts indicates a potential upside of 107.3% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read more